In 2019, Sistema acquired an equity interest in JSC Pharmaceutical Enterprise Obolenskoe (OBL Pharm). The stake was acquired jointly with VTB Bank and management of OBL Pharm from Alvansa Ltd, which is majority-owned by Gazprombank and UFG Private Equity. Sistema invested a total of RUB 1.83 billion in the acquisition of OBL Pharm. The investment consortium consisting of Sistema, VTB and members of the OBL Pharm management team collectively acquired 95.14% of OBL Pharm for a total investment of RUB 15.5 billion. In April 2019 Russian Direct Investment Fund (RDIF), the Russia-China Investment Fund and leading Middle Eastern funds joined the project having invested over RUB 4 billion.
OBL Pharm is one of the leading Russian pharmaceutical companies that develops, manufactures and promotes the latest high-quality medications in compliance with GMP and ISO standards. It produces over 150 prescription and OTC drugs in several therapeutic areas: gastroenterology, cardiology, phlebology, pain relief, insomnia, neurology, male health and others. The company's portfolio includes both innovative products and generics.
It has two production facilities in Obolensk in the Moscow region. Production capacity of the new plant opened in 2019 in Obolensk is 120 mln packages: 1.6 bn pills, 120 mln capsules and 15 mln pouches a year, which is three times greater than the capacity of the legacy facility.